$HRMY
Harmony Biosciences Holdings Inc

2020 Q4 Form 10-Q Financial Statement

#000156459020053320 Filed on November 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $56.29M $45.61M
YoY Change
Cost Of Revenue $9.920M $7.890M
YoY Change
Gross Profit $46.37M $37.72M
YoY Change
Gross Profit Margin 82.38% 82.7%
Selling, General & Admin $30.99M $23.11M $25.47M
YoY Change -9.26%
% of Gross Profit 66.83% 61.27%
Research & Development $7.620M $4.230M $4.336M
YoY Change -2.44%
% of Gross Profit 16.43% 11.21%
Depreciation & Amortization $4.380M $1.970M
YoY Change 45.51%
% of Gross Profit 9.45% 5.22%
Operating Expenses $38.61M $27.34M $29.80M
YoY Change -8.27%
Operating Profit $7.760M $10.38M -$29.80M
YoY Change -134.83%
Interest Expense -$7.970M -$6.946M -$2.095M
YoY Change 231.55%
% of Operating Profit -102.71% -66.92%
Other Income/Expense, Net $0.00 -$1.525M
YoY Change
Pretax Income -$210.0K $1.909M -$31.90M
YoY Change -105.98%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$210.0K $1.909M -$31.90M
YoY Change -105.98%
Net Earnings / Revenue -0.37% 4.19%
Basic Earnings Per Share -$0.14 -$5.26
Diluted Earnings Per Share -$3.691K -$0.14 -$5.26
COMMON SHARES
Basic Shares Outstanding 56.89M 30.21M 7.777M
Diluted Shares Outstanding 30.21M 7.777M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $228.6M $221.7M
YoY Change
Cash & Equivalents $228.6M $221.7M $102.0M
Short-Term Investments
Other Short-Term Assets $1.302M $5.625M
YoY Change 398.85%
Inventory $3.823M $2.311M
Prepaid Expenses $6.959M $4.240M
Receivables $22.18M $16.33M
Other Receivables $0.00 $0.00
Total Short-Term Assets $262.9M $250.2M
YoY Change 734.65%
LONG-TERM ASSETS
Property, Plant & Equipment $938.0K $1.038M
YoY Change -29.47%
Goodwill
YoY Change
Intangibles $162.3M $66.63M
YoY Change 124.9%
Long-Term Investments
YoY Change
Other Assets $152.0K $1.418M
YoY Change -83.85%
Total Long-Term Assets $164.2M $69.83M
YoY Change 118.31%
TOTAL ASSETS
Total Short-Term Assets $262.9M $250.2M
Total Long-Term Assets $164.2M $69.83M
Total Assets $427.1M $320.1M
YoY Change 300.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.556M $9.347M
YoY Change -59.81%
Accrued Expenses $122.7M $17.20M
YoY Change 2131.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $134.5M $31.79M
YoY Change 576.35%
LONG-TERM LIABILITIES
Long-Term Debt $194.3M $192.9M
YoY Change 98.32%
Other Long-Term Liabilities $1.105M $900.0K
YoY Change 577.91%
Total Long-Term Liabilities $195.4M $193.8M
YoY Change 98.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $134.5M $31.79M
Total Long-Term Liabilities $195.4M $193.8M
Total Liabilities $329.9M $225.5M
YoY Change 178.89%
SHAREHOLDERS EQUITY
Retained Earnings -$488.2M
YoY Change 15.45%
Common Stock $585.4M $582.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $97.18M $94.55M -$384.9M
YoY Change
Total Liabilities & Shareholders Equity $427.1M $320.1M
YoY Change 300.25%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$210.0K $1.909M -$31.90M
YoY Change -105.98%
Depreciation, Depletion And Amortization $4.380M $1.970M
YoY Change 45.51%
Cash From Operating Activities $10.04M $8.840M
YoY Change -121.16%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$2.000M $0.00
YoY Change 0.0%
Cash From Investing Activities -$2.000M $0.00
YoY Change -97.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $135.4M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.160M 136.6M
YoY Change -101.59%
NET CHANGE
Cash From Operating Activities 10.04M 8.840M
Cash From Investing Activities -2.000M 0.000
Cash From Financing Activities -1.160M 136.6M
Net Change In Cash 6.880M 145.5M
YoY Change -113.38%
FREE CASH FLOW
Cash From Operating Activities $10.04M $8.840M
Capital Expenditures $0.00 $0.00
Free Cash Flow $10.04M $8.840M
YoY Change -63.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address City Or Town
EntityAddressCityOrTown
Plymouth Meeting
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19462
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
539-9800
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 value per share
dei Trading Symbol
TradingSymbol
HRMY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56889111
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221740000
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16326000
CY2020Q3 us-gaap Inventory Net
InventoryNet
2311000
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4240000
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
5625000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
250242000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1038000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
66625000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1418000
CY2020Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
69831000
CY2020Q3 us-gaap Assets
Assets
320073000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9347000
CY2020Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5243000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17200000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
115000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
31790000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19892000
CY2020Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
305000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
287000
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001802665
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
582535000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-422862000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-422862000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106703000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
27477000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12560000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26280000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
27339000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11829000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
423630000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56888625
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7787470
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56888625
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7787470
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45609000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103454000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7890000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
17820000
CY2020Q3 us-gaap Gross Profit
GrossProfit
37719000
us-gaap Gross Profit
GrossProfit
85634000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4230000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4336000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62319000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12601000
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12908000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
38297000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10508000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22415000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
29804000
us-gaap Operating Expenses
OperatingExpenses
76406000
us-gaap Operating Expenses
OperatingExpenses
112211000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
10380000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29804000
us-gaap Operating Income Loss
OperatingIncomeLoss
9228000
us-gaap Operating Income Loss
OperatingIncomeLoss
-112211000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-22639000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1525000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3071000
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6946000
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2095000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-20254000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-3326000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1909000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31899000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36736000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-115537000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
1909000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-31899000
us-gaap Net Income Loss
NetIncomeLoss
-36736000
us-gaap Net Income Loss
NetIncomeLoss
-115537000
CY2020Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6013000
CY2019Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
9027000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
26904000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
25656000
us-gaap Profit Loss
ProfitLoss
-115537000
us-gaap Depreciation
Depreciation
294000
us-gaap Depreciation
Depreciation
300000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5560000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
965000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
17000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4104000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40926000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-63640000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-141193000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-18.15
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-18.15
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30212959
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7777100
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15324362
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7777100
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30212959
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7777100
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15324362
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7777100
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
318510205
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
411275000
hrmy Temporary Equity Share Converted To Permanent Equity
TemporaryEquityShareConvertedToPermanentEquity
318510205
hrmy Temporary Equity Value Converted To Permanent Equity
TemporaryEquityValueConvertedToPermanentEquity
444715000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
135435000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
444716000
hrmy Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
5468000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
283000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1870000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
167000
CY2020Q3 hrmy Temporary Equity Share Converted To Permanent Equity
TemporaryEquityShareConvertedToPermanentEquity
318510205
CY2020Q3 hrmy Temporary Equity Value Converted To Permanent Equity
TemporaryEquityValueConvertedToPermanentEquity
444715000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-483362000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
135435000
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
444716000
CY2020Q3 hrmy Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
5468000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1073000
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
17000
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
293000000
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
324201000
CY2019Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
318510205
CY2019Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
400876000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-242673000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1104000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-384913000
CY2019Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
293000000
CY2019Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
342213000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-343626000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
407000
us-gaap Profit Loss
ProfitLoss
-36736000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000
hrmy Payments To Acquire In Process Research And Development Other Than Through Business Combination
PaymentsToAcquireInProcessResearchAndDevelopmentOtherThanThroughBusinessCombination
50000000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
50000000
us-gaap Share Based Compensation
ShareBasedCompensation
1870000
us-gaap Share Based Compensation
ShareBasedCompensation
1104000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
396000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3109000
us-gaap Paid In Kind Interest
PaidInKindInterest
1493000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1020000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
382000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12071000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1223000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
916000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8169000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-179000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
476000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-75000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2987000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
7491000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7738000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2946000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
30000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
69000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13032000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51449000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
113000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50113000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
147628000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
11021000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
50000000
hrmy Payment Of Preferred Stock Issuance Costs
PaymentOfPreferredStockIssuanceCosts
1132000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
200000000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
75000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5804000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
4309000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
102538000
hrmy Payments Of Extinguishment Of Debt Exit Fees
PaymentsOfExtinguishmentOfDebtExitFees
18047000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
283000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
167000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
17000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
210317000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
119559000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
197283000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17997000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25207000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84023000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
222490000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102020000
us-gaap Interest Paid Net
InterestPaidNet
19549000
us-gaap Interest Paid Net
InterestPaidNet
108000
hrmy Cash Paid For Milestones
CashPaidForMilestones
50000000
hrmy Warrant Financing
WarrantFinancing
2359000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1867000
us-gaap Advertising Expense
AdvertisingExpense
8576000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.83%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of our Condensed Consolidated Financial Statements in conformity with GAAP requires us to make estimates that affect the amounts and disclosures in the Condensed Consolidated Financial Statements, including the notes thereto, and elsewhere in this report.&nbsp;&nbsp;Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.67%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits in this institution may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its trade receivables related to its product sales. The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of September&#160;30, 2020, three customers accounted for 100% of gross accounts receivable, Caremark LLC (&#8220;CVS Caremark&#8221;), which accounted for 33% of gross accounts receivable; PANTHERx Specialty Pharmacy LLC (&#8220;Pantherx&#8221;), which accounted for 38% of gross accounts receivable; and Accredo Health Group, Inc. (&#8220;Accredo&#8221;), which accounted for 29% of gross accounts receivable. As of December&#160;31, 2019, customers accounted for % of gross accounts receivable; CVS Caremark, which accounted for % of gross accounts receivable, and Pantherx, which accounted for of gross accounts receivable. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September&#160;30, 2020, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 40% of gross product revenues; Pantherx accounted for 34% of gross product revenues; and Accredo accounted for 26% of gross product revenues. For the nine months ended September 30, 2019, revenues were zero.</p> <p style="margin-bottom:0pt;margin-top:1pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019, two customers accounted for 91% of gross accounts receivable; CVS Caremark, which accounted for 72% of gross accounts receivable, and Pantherx, which accounted for 19% of gross accounts receivable. </p> <p style="margin-bottom:0pt;margin-top:1pt;text-indent:5.67%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on a single source supplier for its product, product candidates and their active pharmaceutical ingredient. </p>
CY2020Q3 hrmy Common Stock Number Of Shares Subject To Forfeiture Provisions
CommonStockNumberOfSharesSubjectToForfeitureProvisions
1217285
CY2019Q4 us-gaap Share Based Compensation
ShareBasedCompensation
8400000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P5Y
CY2019Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
75000000
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
938000
CY2020Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
7297000
CY2020Q3 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
3983000
CY2019Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
713000
CY2020Q3 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2119000
hrmy Capitalized Research And Development Expense
CapitalizedResearchAndDevelopmentExpense
1323000
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
410239
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-8.215
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1217
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8375000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2815000
CY2019Q3 hrmy License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
2000000
CY2019Q4 us-gaap Inventory Gross
InventoryGross
1088000
CY2020Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
55000
CY2019Q4 hrmy License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
75000000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P9Y
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
7407000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
7407000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
7407000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
7407000
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
135435000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive
7407000
CY2020Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
75000000
us-gaap Advertising Expense
AdvertisingExpense
2445000
CY2020Q3 us-gaap Advertising Expense
AdvertisingExpense
3138000
CY2019Q3 us-gaap Advertising Expense
AdvertisingExpense
1343000
CY2020Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
185000
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
384000
CY2020Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1105000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
417000
CY2020Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1076000
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
287000
CY2020Q3 us-gaap Inventory Gross
InventoryGross
2366000
CY2019Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
894000
CY2020Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1782000
CY2019Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1547000
CY2020Q3 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1881000
CY2019Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
510000
CY2019Q4 hrmy Accrued Debt Issuance Costs Current
AccruedDebtIssuanceCostsCurrent
638000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
138000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
260000
CY2019Q4 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
3466000
us-gaap Operating Lease Expense
OperatingLeaseExpense
516000
us-gaap Operating Lease Expense
OperatingLeaseExpense
442000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
363000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
443000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
443000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
443000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
184000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1876000
CY2019 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2017Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1690672
CY2017Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2017Q3 hrmy Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1690672
CY2017Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
139000
CY2020Q3 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
1-for-8.215
CY2020Q3 hrmy Preferred Stock Conversion Ratio
PreferredStockConversionRatio
0.1217
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2375218
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.39
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.38
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1330000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2266000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
407000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2812135
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
36003
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
99885
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5051465
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.22
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
23.01
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.22
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.07
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.40
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M25D
hrmy Share Based Compensation Expense Income
ShareBasedCompensationExpenseIncome
-2000
hrmy Share Based Compensation Expense Income
ShareBasedCompensationExpenseIncome
4000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5500
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9530
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9580
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9930
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0032
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0160
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0051
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0259
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1104000
CY2020Q3 hrmy Future Share Based Compensation Expense Remainder Of Fiscal Year
FutureShareBasedCompensationExpenseRemainderOfFiscalYear
4687000
CY2020Q3 hrmy Future Share Based Compensation Expense Year One
FutureShareBasedCompensationExpenseYearOne
9645000
CY2020Q3 hrmy Future Share Based Compensation Expense Year Two
FutureShareBasedCompensationExpenseYearTwo
9514000
CY2020Q3 hrmy Future Share Based Compensation Expense Year Three
FutureShareBasedCompensationExpenseYearThree
8541000
CY2020Q3 hrmy Future Share Based Compensation Expense Year Four
FutureShareBasedCompensationExpenseYearFour
7809000
CY2020Q3 hrmy Future Share Based Compensation Expense Year Five
FutureShareBasedCompensationExpenseYearFive
5001000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5461704
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39820340
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5461704
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38656648
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1525000
CY2020Q3 us-gaap Warrants And Rights Outstanding Change In Valuation Technique
WarrantsAndRightsOutstandingChangeInValuationTechnique
false

Files In Submission

Name View Source Status
0001564590-20-053320-index-headers.html Edgar Link pending
0001564590-20-053320-index.html Edgar Link pending
0001564590-20-053320.txt Edgar Link pending
0001564590-20-053320-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hrmy-10q_20200930.htm Edgar Link pending
hrmy-20200930.xml Edgar Link completed
hrmy-20200930.xsd Edgar Link pending
hrmy-20200930_cal.xml Edgar Link unprocessable
hrmy-20200930_def.xml Edgar Link unprocessable
hrmy-20200930_lab.xml Edgar Link unprocessable
hrmy-20200930_pre.xml Edgar Link unprocessable
hrmy-ex109_551.htm Edgar Link pending
hrmy-ex311_173.htm Edgar Link pending
hrmy-ex312_172.htm Edgar Link pending
hrmy-ex321_170.htm Edgar Link pending
hrmy-ex322_171.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending